The role of thiamine in cancer: Possible genetic and cellular signaling mechanisms

Cancer Genomics and Proteomics

Volumn 10, Issue 4, 2013, Pages 169-186

  Luong, Khanh Vinh Quõc ^a   NguyěN, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Cancer; Review; Thiamine; Transketolase; Tumor; Vitamin B1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BENFOTIAMINE; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; OXOGLUTARATE DEHYDROGENASE; PROSTAGLANDIN; PROTEIN P53; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSKETOLASE;

CANCER RESISTANCE; CANCER RISK; CELL SURVIVAL; CELL TRANSFORMATION; COLORECTAL CARCINOMA; CYTOTOXICITY; DIET SUPPLEMENTATION; DNA DAMAGE; DNA STRAND BREAKAGE; DOWN REGULATION; ERYTHROCYTE MEMBRANE; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GENETIC VARIABILITY; GLUCOSE INTOLERANCE; HEREDITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; LIPID PEROXIDATION; LUNG CANCER; LYMPHANGIOGENESIS; NEOPLASM; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PREGNANCY DIABETES MELLITUS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; THIAMINE DEFICIENCY; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA; WERNICKE ENCEPHALOPATHY;

EID: 84882338057     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (256)

1. Brinkman MT, Karagas MR, Zen MS, Schned A, Reulen RC and Zeegers MP: Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire study. Cancer Causes Control 21: 609-619, 2010.
2. Kaaks R, Tuyns AJ, Haelterman M and Riboli E: Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer 78: 415-420, 1998.
3. Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L and Goodman MT: Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control 14: 859-470, 2003.
4. Jedrychowski W, Steindorf K, Popiela T, Wahrendorf J, Tobiasz-Adamczyk B, Kulig J and Penar A: Alcohol consumption and the risk of colorectal cancer at low levels of micronutrient intake. Med Sci Monit 8: CR357-363, 2002.
5. Du S, Shi L, Zhang H and He S: Relationship between dietary nutrients intakes and human prostate cancer. Wei Sheng Yan Jiu 26: 122-125, 1997. (Chinese).
6. Hargreaves MK, Baquet C and Gamshadzahi A: Diet, nutritional status, and cancer risk in American blacks. Nutr Cancer 12: 1-28, 1989.
7. Georgiannos SN, Weston PMT and Goode AW: Micronutrients in gastrointestinal cancer. Br J Cancer 68: 1195-1198, 1993.
8. Nesterova VI and Chebotareva MA: Thiamine content and enzyme activity in blood cells in leukemia]. Vopr Med Khim 22: 732-735, 1976. (in Russian).
9. Basu TK and Dickerson JW: The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 33: 250-252, 1976.
10. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS and Schirmer WJ: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57: 4242-4248, 1997.
11. Raïs B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Lee WN, Boros LG and Cascante M: Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett 456: 113-118, 1999.
12. Crim JA, Buskirk HH and Petering HG: The effect of B vitamin and protein intake of the rat on the antitumor activity of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone). Cancer Res 27: 1109-1114, 1967.
13. Ganapathy V, Smith SB and Prasad PD: SLC19: the folate/thiamine transporter family. Pflugers Arch 447: 641-646, 2004.
14. Dutta B, Huang W, Molero M, Kekuda R, Leibach FH, Devoe LD, Ganapathy V and Prasad PD: Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 274: 31925-31929, 1999.
15. Rajgopal A, Edmondnson A, Goldman ID and Zhao R: SLA19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta 1537: 175-178, 2001.
16. Liu S, Huang H, Lu X, Golinski M, Comesse S, Watt D, Grossman RB and Moscow JA: Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. Mol Cancer Res 1: 665-1673, 2003.
17. Liu S, Stromberg A, Tai H-H and Moscow JA: Thiamine transporter gene expression and exgogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2: 477-487, 2004.
18. Liu X, Lam EK, Wang X, Zhang J, Cheng YY, Lam YW, Ng EK, Yu J, Chan FK, Jin H and Sung JJ: Promoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancer. Tumour Biol 30: 242-248, 2009.
19. Ikehata M, Ueda K and Iwakawa S: Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines. Biol Pharm Bull 35: 301-307, 2012.
20. Sweet R, Paul A and Zastre J: Hypoxia induced upregulation and function of the thiamine transporter, SLC19A3 in a breast cancer cell line. Cancer Biol Ther 10: 1101-1111, 2010.
21. Ng EK, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM and Kwong A: Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLos ONE 6: e22233, 2011.
22. Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD and Goldman ID: Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 276: 1114-1118, 2001.
23. Zhao R, Gao F and Goldman ID: Reduced folate carrier transport thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J physiol 282: C1512-1517, 2002.
24. Yang R, Qin J, Hoang BH, Healy JH and Gorlik R: Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 466: 2046-2051, 2008.
25. Figueiredo JC, Levine AJ, Lee WH, Conti DV, Poynter JN, Campbell PT, Duggan D, Lewinger JP, Martinez ME, Ulrich CM, Newcomb P, Potter J, Limburg PJ, Hopper J, Jenkins MA, Le Marchand L, Baron JA and Haile RW: Genes involved with folate uptake and distribution and their association with colorectal cancer risk. Cancer Causes Control 21: 597-608, 2010.
26. Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE and Adjei AA: Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after premetrexed-based therapy in non-small cell lung cancer: a North central cancer treatment group-based exploratory study. J Thorac Oncol 5: 1346-1353, 2010.
27. Abdel-Haleem AM, El-Zeiry MI, Mahran LG, Abou-Aisha K, Rady MH, Rohde J, Mostageer M and Spahn-Langguth H: Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients. PLos ONE 6: e21820, 2011.
28. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, Davis M, Lane JA, Donovan J, Smith GD, Neal DE, Hamdy FC, Gudmundsson J, Sulem P, Rafnar T, Benediktsdottir KR, Eeles RA, Guy M, Kote-Jarai Z; UK Genetic Prostate Cancer Study Group, Morrison J, Al Olama AA, Stefansson K, Easton DF and Martin RM: Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systemic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 18: 2528-2539, 2009.
29. Kastrup IB, Worm J, Ralfkiaer E, Guldberg P and Grønbæk K: Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol 80: 61-66, 2008.
30. De Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, Peters GJ and Pieters R: Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 113: 2284-2289, 2009.
31. Galbiatti AL, Ruiz MT, Rezende Pinto D, Raposo LS, Maníglia JV, Pavarino-Bertelli EC and Goloni-Bertollo EM: A80G polymorphism of reduced folate carrier 1 (RFC1) gene and head and neck squamous cell carcinoma etiology in Brazilian population. Mol Biol Rep 38: 1071-1078, 2011.
32. Sirachainan N, Wongruangsri S, Kajanachumpol S, Pakakasama S, Visudtibhan A, Nuchprayoon I, Lusawat A, Phudhicharoenrat S, Shuangshoti S and Hongeng S: Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children. Cancer Detect Prev 32: 72-78, 2008.
33. Corona G, Giannini F, Fabris M, Toffoli G and Boiocchi M: Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 75: 125-133, 1998.
34. Meléndez RR: Importance of water-soluble vitamins as regulatory factors of genetic expression. Rev Invest Clin 54: 77-83, 2002. (in Spanish).
35. Trebukhina RV, Tumanov VN, Avdeǐchik LA, Bobko IN and Tsabenko II: Transketolase activity and thiamine diphosphate content in oncological patients. Vopr Med Khim 29: 85-90, 1983. (in Russian).
36. Lin CC, Chen LC, Tseng VS, Yan JJ, Lai WW, Su WP, Lin CH, Huang CY and Su WC: Malignant pleural effusion cells aberrant glucose metabolism gene expression. Eur Respir J 37: 1453-1465, 2011.
37. Xu X, Zur Hausen A, Coy JF and Löchelt M: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124: 1330-1337, 2009.
38. Zerilli M, Amato MC, Martorana A, Cabibi D, Coy JF, Cappello F, Pompei G, Russo A, Giordano C and Rodolico V: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer 113: 936-944, 2008.
39. Fröhlich E, Fink I and Wahl R: Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. Invest New Drugs 27: 297-303, 2009.
40. Völker HU, Scheich M, Schmausser B, Kämmerer U and Eck M: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 264: 1431-1436, 2007.
41. Zhang S, Yue JX, Yang JH, Cai PC and Kong WJ: Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma. Cancer Biol Ther 7: 517-522, 2008.
42. Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M and Zur Hausen A: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 43: 719-724, 2011.
43. Schultz H, Kähler D, Branscheid D, Vollmer E, Zabel P and Goldmann T: TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn Pathol 3: 35, 2008.
44. Staiger WI, Coy JF, Grobholz R, Hofheinz RD, Lukan N, Post S, Schwarzbach MH and Willeke F: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 16: 657-661, 2006.
45. Zhang S, Yang JH, Guo CK and Cai PC: Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253: 108-114, 2007.
46. Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A and Cascante M: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One 6: e25323, 2011.
47. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P and Coy JF: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94: 578-585, 2006.
48. Wu HT, Allie N, Myer L and Govender D: Anaplastic nephroblastomas express transketolase-like enzyme 1. J Clin Pathol 62: 460-463, 2009.
49. Földi M, Stickeler E, Bau L, Kretz O, Watermann D, Gitsch G, Kayser G, Zur Hausen A and Coy JF: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep 17: 841-845, 2007.
50. Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Häusler SF, Dombrowski Y and Kapp M, Dietl J, Honig A: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res 30: 1653-1659, 2010.
51. Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kapp M, Horn E, Dietl J and Kammerer U: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 17: 101-106, 2007.
52. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J and Voelker HU: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 139: 72-78, 2008.
53. Chen H, Yue JX, Yang SH, Ding H, Zhao RW and Zhang S: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 28: 43, 2009.
54. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK and Califano JA: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16: 857-866, 2010.
55. Völker HU, Hagemann C, Coy J, Wittig R, Sommer S, Stojic J, Haubitz I, Vince GH and Kämmerer U, Monoranu CM: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol 130: 50-57, 2008.
56. Mitschke L, Parthier C, Schröder-Tittmann K, Coy J, Lüdtke S and Tittmann K: The crystal structure of human transketolase and new insights into its mode of action. J Biol Chem 285: 31559-31570, 2010.
57. Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C and Crook T: High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 106: 397-404, 2012.
58. Li Q, Kawamura K,Yamanaka M, Okamoto S,Yang S,Yamauchi S, Fukamachi T, Kobayashi H, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K and Tagawa M: Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19: 218-228, 2012.
59. Abedi-Ardekani B, Kamangar F, Sotoudeh M, Villar S, Islami F, Aghcheli K, Nasrollahzadeh D, Taghavi N, Dawsey SM, Abnet CC, Hewitt SM, Fahimi S, Saidi F, Brennan P, Boffetta P, Malekzadeh R and Hainaut P: Extremely high tp53 mutation load in esophageal squamous cell carcinoma in golestan province, iran. PLoS One 6: e29488, 2011.
60. King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go VL, Reber HA, Eibl G and Hines OJ: Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim Biophys Acta 1823: 593-604, 2012.
61. Koushik A, Platt RW and Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13: 11-22, 2004.
62. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML and Wu XT: P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121: 1481-1486, 2007.
63. Li DB, Wei X, Jiang LH, Wang Yand Xu F: Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer. Genet Mol Res 9: 1599-1605, 2010.
64. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V and Murray S: TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 19: 1840-1847, 2010.
65. Gu Y, Zhou X and Zhang SL: Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk. Genet Mol Res 10: 3609-3619, 2011.
66. Li MS, Liu JL, Wu Y, Wang P and Teng H: Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk. Genet Mol Res 10: 2924-2933, 2011.
67. Lo PK, Chen JY, Tang PP, Lin J, Lin CH, Su LT, Wu CH, Chen TL, Yang Y and Wang FF: Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53. J Biol Chem 276: 37186-37193, 2001.
68. McLure KG, Takagi M and Kastan MB: NAD+ modulates p53 DNA binding specificity and function. Mol Cellular Biol 24: 9958-9967, 2004.
69. Yang Z, Ge J, Yin W, Shen H, Liu H and GuoY: The expression of p53, MDM2 and Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or elevated pressure. Yan Ke Xue Bao 20: 259-263, 2004. (in Chinese).
70. Masutani M, Nakagama H and Sugimura T: Poly(ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer 38: 339-348, 2003.
71. Tong WM, Yang YG, Cao WH, Galendo D, Frappart L, Shen Y and Wang ZQ: Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 26: 3857-3867, 2007.
72. Tong WM, Cortes U, Hande MP, Ohgaki H, Cavalli LR, Lansdorp PM, Haddad BR and Wang ZQ: Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res 62: 6990-6996, 2002.
73. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME and Dritschilo A: Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 50: 38-43, 1990.
74. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S and Taniguchi T: Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37: 223-227, 1991.
75. Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, AdachiY, Imamura A, Imai K and Shinomura Y: Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 42: 2374-2381, 2006.
76. Quiles-Perez R, Muñoz-Gámez JA, Ruiz-Extremera A, O'Valle F, Sanjuán-Nuñez L, Martín-Alvarez AB, Martín-Oliva D, Caballero T, Muñoz de Rueda P, León J, Gonzalez R, Muntané J, Oliver FJ and Salmerón J: Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 51: 255-266, 2010.
77. Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A and Albanell J: Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 23: 1156-1164, 2012.
78. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Gore L, Liu AK and Foreman NK: PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer 53: 1227-1230, 2009.
79. Barnett JC, Bean SM, Nakayama JM, Kondoh E, Murphy SK and Berchuck A: High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. Obstet Gynecol 115: 49-54, 2010.
80. Gonçalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, Chaffanet M, Viens P, Birnbaum D and Bertucci F: Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 127: 273-281, 2011
81. Zhang Q, LiY, Li X, Zhou W, Shi B, Chen H andYuan W: PARP-1 Val762Ala polymorphism, CagA+ H. pylori infection and risk for gastric cancer in Han Chinese population. Mol Biol Rep 36: 1461-1467, 2009.
82. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K and Hu JJ: The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64: 6344-6348, 2004.
83. Hao B, Wang H, Zhou K, LiY, Chen X, Zhou G, ZhuY, Miao X, Tan W, Wei Q, Lin D and He F: Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64: 4378-4384, 2004.
84. Zhang X, Miao X, Liang G, Hao B, WangY, Tan W, LiY, Guo Y, He F, Wei Q and Lin D: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65: 722-726, 2005.
85. Jin XM, Kim HN, Lee IK, Park KS, Kim HJ, Choi JS, Juhng SW and Choi C: PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males. BMC Med Genet 11: 38, 2010.
86. Wang XG, Wang ZQ, Tong WM and Shen Y: PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 354: 122-126, 2007.
87. Yu H, Ma H, Yin M and Wei Q: Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. Genet Epidemiol 36: 56-65, 2011.
88. Shin BH, Choi SH, Cho EY, Shin MJ, Hwang KC, Cho HK, Chung JH and JangY: Thiamines attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes. Mol Cells 18: 133-140, 2004.
89. Yadav UCS, Kalariya NM, Srivastava SK and Ramana KV: Protective role of benfotiamine, a fat soluble vitamin B1 analogue, in the lipopolysaccharide- induced cytotoxic signals in murine macrophages. Free Radic Biol Med 48: 1423-1434, 2010.
90. Frédérich M, Delvaux D, Gigliobianco T, Gangolf M, Dive G, Mazzucchelli G, Elias B, De Pauw E, Angenot L, Wins P and Bettendorff L: Thiaminylated adenine nucleotides. FEBS J 276: 3256-3268, 2009.
91. Tanaka T, Yamamoto D, Sato T, Tanaka S, Usui K, Manabe M, Aoki Y, Iwashima Y, SaitoY, Mino Y and Deguchi H: Adenosine thiamine triphosphate (AThTP) inhibits Poly(ADP-Ribose) polymerase-1 (PARP-1) activity. J Nutr Sci Vitaminol 57: 192-196, 2011.
92. Kamata T: Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100: 1382-1388, 2009.
93. Block K, Gorin Y, New DD, Eid A, Chelmicki T, Reed A, Choudhury GG, Parekh DJ and Abboud HE: The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol 176: 2447-2455, 2010.
94. 2-M cell cycle progression. Cancer Res 69: 2647-2654, 2009.
95. Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D and Hakim G: NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res 43: 1111-1121, 2009.
96. Hong J, Resnick M, Behar J, Wang LJ, Wands J, DeLellis RA, Souza RF, Spechler SJ and Cao W: Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol 299: G697-706, 2010.
97. Lu CL, Qiu JL, Huang PZ, Zou RH, Hong J, Li BK, Chen GH and Yuan YF: NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumour Biol 32: 1173-1182, 2011.
98. Kim J, Koyanagi T and Mochly-Rosen D: PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate 71: 946-954, 2011.
99. Wang R, Dashwood WM, Nian H, Löhr CV, Fischer KA, Tsuchiya N, Nakagama H, Ashktorab H and Dashwood RH: NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP). Int J Cancer 128: 2581-2590, 2011.
100. Hsieh CH, Shyu WC, Chiang CY, Kuo JW, Shen WC and Liu RS: NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One 6: e23945, 2011.
101. Yin L, Kosugi M and Kufe D: Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood 119: 810-816, 2012.
102. Naoe T, Takeyama K,Yokozawa T, Kiyoi H, Seto M, Uike N, Ino T, Utsunomiya A, Maruta A, Jin-nai I, Kamada N, Kubota Y, Nakamura H, Shimazaki C, Horiike S, Kodera Y, Saito H, Ueda R, Wiemels J and Ohno R: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6: 4091-4095, 2000.
103. Fern L, Pallis M, Ian Carter G, Seedhouse C, Russell N and Byrne J: Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 126: 63-71, 2004.
104. Hamajima N, Matsuo K, Iwata H, Shinoda M,YamamuraY, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y, Ogura M, Ando M, Sugimura Y and Tajima K: NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7: 103-108, 2002.
105. Chan EC, Lam SY, Fu KH and Kwong YL: Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 162: 10-20, 2005.
106. Lan Q, Zheng T, Shen M, ZhangY, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P and Chanock S: Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 121: 161-168, 2007.
107. Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trümper L, Loeffler M, Brockmöller J and German Study Group for High-Grade Non-Hodgkin Lymphoma: A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res 70: 2328-2338, 2010.
108. Gra OA, Glotov AS, Kozhekbaeva Zh, Makarova OV and Nasedkina TV: [Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia]. Mol Biol (Mosk) 42: 214-225, 2008. (in Russian).
109. Seibold P, Hein R, Schmezer P, Hall P, Liu J, Dahmen N, Flesch-Janys D, Popanda O and Chang-Claude J: Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer 129: 1467-1476, 2011.
110. Malik MA, Zargar SA and Mittal B: Role of NQO1 609C>T and NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley. DNA Cell Biol 30: 297-303, 2011.
111. Galdhar NR and Pawar SS: Hepatic drug metabolism and lipid peroxidation in thiamine deficient rats. Int J Vitam Nutr Res 46: 14-23, 1976.
112. Fraser DA, Hessvik NP, Nikolič N, Aas V, Hanssen KF, Bøhn SK, Thoresen GH and Rustan AC: Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations. Genes Nutr 7: 459-692, 2012.
113. Grosse W 3rd and Wade AE: The effect of thiamine consumption on liver microsomal drug-metabolizing pathways. J Pharmacol Exp Ther 176: 758-765, 1971
114. Sella T, Chodick G, Barchana M, Heymann AD, Porath A, Kokia E and Shalev V: Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel. Cancer Causes Control 22: 1513-1520, 2011.
115. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I and Hammar N: Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22: 1163-1171, 2011.
116. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R and La Vecchia C: The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 21: 835-841, 2011.
117. Zendehdel K, Nyrén O, Ostenson CG, Adami HO, Ekbom A and Ye W: Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95: 1797-1800, 2003.
118. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, Patterson CC and Keen H: Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92: 2070-2075, 2005.
119. Huang W, Ren H, Ben Q, Cai Q, Zhu W and Li Z: Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control 23: 263-72, 2012.
120. Tian T, Zhang LQ, Ma XH, Zhou JN and Shen J: Diabetes Mellitus and Incidence and Mortality of Gastric Cancer: A Meta-Analysis. Exp Clin Endocrinol Diabetes 120: 217-223, 2012.
121. Luo W, Cao Y, Liao C and Gao F: Diabetes mellitus and the incidence and mortality of colorectal cancer: A meta-analysis of twenty four cohort studies. Colorectal Dis 14: 1307-1312, 2012.
122. Wang P, Kang D, Cao W, Wang Y and Liu Z: Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28: 109-122, 2012.
123. Jing W, Jin G, Zhou X, Zhou Y, Zhang Y, Shao C, Liu R and Hu X: Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 21: 24-31, 2012.
124. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, Wang C and Sun S: Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 12: 1061-1065, 2011.
125. Habib SL, Prihoda TJ, Luna M and Werner SA: Diabetes and risk of renal cell carcinoma. J Cancer 3: 42-48, 2012.
126. Watson JD and Dako DY: Erythrocyte transketolase activity in adult Ghanaian subjects. Clin Chim Acta 59: 55-61, 1975.
127. Valerio G, Franzese A, Poggi V, Patrini C, C, Laforenza U and Tenore A: Lipophylic thiamine treatment in long-standing insulin-dependent diabetes mellitus. Acta Diabetol 36: 73-76, 1999.
128. Berant M, Berkovitz D, Mandel H, Zinder O and Mordohovich D: Thiamine status of the offspring of diabetic rats. Pediatr Res 23: 574-575, 1988.
129. Clark JA, Burny I, Sarnaik AP and Audhya TK: Acute thiamine deficiency in diabetic ketoacidosis: Diagnosis and management. Pediatr Crit Care Med 7: 595-599. 2006.
130. Oriot D, Wood C, Gottesman R and Huault G: Severe lactic acidosis related to acute thiamine deficiency. JPEN J Parenter Enteral Nutr 15: 105-109, 1991.
131. Saito N, Kimura M, Kuchiba A, and Itokawa Y: Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol 33: 421-430, 1987.
132. Kjøsen BMS and Seim SH: The transketolase assay of thiamine in some diseases. Am J Clin Nutr 30: 1591-1596, 1977.
133. Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, Ahmed A, Rayman G and Bodmer CW: High prevalence of low thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 50: 2164-2170, 2007.
134. Briggs MH: Vitamin and coenzyme content of hepatomas induced by buter yellow. Nature 187: 249-250, 1960.
135. Ayre JE and Bauld WA: Thiamine Deficiency and High Estrogen Findings in Uterine Cancer and in Menorrhagia. Science 103: 441-445, 1945.
136. Seligmann H, Levi R, Konijn AM and Prokocimer M: Thiamine deficiency in patients with B-chronic lymphocytic leukaemia: a pilot study. Postgrad Med J 77: 582-585, 2001.
137. Bruce WR, Cirocco M, Giacca A, Kim YI, Marcon N and Minkin S: A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation. Br J Cancer 93: 639-946, 2005.
138. Ostrovskiǐ Iu M, Trebukhina RV and Mikhal'tsevich GN: Tumor and body interrelationships in 14C-thiamine utilization]. Biull Eksp Biol Med 88: 708-710, 1979. (in Russian).
139. Boros LG, Brandes JL, Lee WN, Cascante M, Puigjaner J, Revesz E, Bray TM, Schirmer WJ and Melvin WS: Thiamine supplementation to cancer patients: a double edged sword. Anticancer Res 18: 595-602, 1998.
140. Pamukcu AM, Yalçiner S, Price JM and Bryan GT: Effects of the coadministration of thiamine on the incidence of urinary bladder carcinomas in rats fed bracken fern. Cancer Res 30: 2671-2674, 1970.
141. Suryo Rahmanto Y, Dunn LL and Richardson DR: Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. Carcinogenesis 28: 2172-2183, 2007.
142. Endo N, Takeda Y, Umemoto N, Kishida K, Watanabe K, Saito M, Kato Y and Hara T: Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates. Cancer Res 48: 3330-3335, 1988.
143. Naujokaitis SA: Thiamine protection of murine L1210 leukemia cells against mechlorethamine cytotoxicity and its relation to the choline uptake system. Res Commun Chem Pathol Pharmacol 32: 317-327, 1981.
144. Trebukhina RV, Koltaniuk TA, Petushok VG, Mikhal'tsevich GN, Lashak LK and Gritsenko EA: [Metabolism of vitamins B1 and PP and their use in oncological practice]. Vopr Med Khim 38: 33-36, 1992. (in Russian).
145. Liu S, Monks NR, Hanes JW, Begley TP, Yu H and Moscow JA: Sensitivity of breast cancer cell lines to recombinant thiaminase I. Cancer Chemother Pharmacol 66: 171-179, 2010.
146. Daily A, Liu S, BaeY, Bhatnagar S and Moscow JA: Linear chain PEGylated recombinant Bacillus thiaminolyticus thiaminase I enzyme has growth inhibitory activity against lymphoid leukemia cell lines. Mol Cancer Ther 10: 1563-1570, 2011.
147. Trebukhina RV, Kravchuk RI, Mikhal'tsevich GN, Petushok VG and Nikitin VS: [Effect of thiamine and its antimetabolite oxythiamine on the proliferative activity of carcinosarcoma Walker 256 cells]. Eksp Onkol 9: 60-63, 1987. (in Russian).
148. Bruce WR, Furrer R, Shangari N, O'Brien PJ, Medline A and Wang Y:
149. Salley JJ, Eshlemann JR and Morgan JH: Effect of chronic thiamine deficiency on oral carcinogenesis. J Dent Res 41: 1405-1413, 1962.
150. Sheline CT: Thiamine supplementation attenuated hepatocellular carcinoma in the Atp7b mouse model of Wilson's disease. Anticancer Res 31: 3395-3399, 2011.
151. Lee BY, Yanamandra K and Bocchini JA Jr: Thiamin deficiency: a possible major cause of some tumors? (review). Oncol Rep 14: 1589-1592, 2005.
152. Comín-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WN, Boros LG and Cascante M: The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 268: 4177-4182, 2001.
153. Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A and Stopper H: Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 378: 283-291, 2008.
154. Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C and von Deimling A: MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9: 671-677, 2007.
155. Zhang Y, Zhao H, Wang Y, Lin Y, Tan Y, Fang X and Zheng L: Non-small cell lung cancer invasion and metastasis promoted by MMP-26. Mol Med Report 4: 1201-1209, 2011.
156. Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y and Jiang T: Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 1411: 108-115, 2011.
157. Garamszegi N, Garamszegi SP and Scully SP: Matrix metalloproteinase-1 contribution to sarcoma cell invasion. J Cell Mol Med 16: 1331-1341, 2012.
158. Hong SW, KangYK, Lee B, Lee WY, JangYG, Paik IW and Lee H: Matrix metalloproteinase-2 and-7 expression in colorectal cancer. J Korean Soc Coloproctol 27: 133-139, 2011.
159. ShinYJ and Kim JH: The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells. PLoS One 7: e30393, 2012.
160. Ghosh S, Basu M and Roy SS: ETS-1 regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell SKOV-3. J Biol Chem 287: 15001-15015, 2012.
161. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E and Scorza R: A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8: 3820-3823, 2002.
162. Xu E, Xia X, Lü B, Xing X, Huang Q, MaY, Wang W and Lai M: Association of matrix metalloproteinase-2 and-9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog 46: 924-929, 2007.
163. Hirata H, Okayama N, Naito K, Inoue R,Yoshihiro S, Matsuyama H, Suehiro Y, Hamanaka Y and Hinoda Y: Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis 25: 2379-2384, 2004.
164. Lu Z, Wang Y, Zhang Q, Zhang X, Wang S, Xie H, Li Y, Jiao B and Zhang J: Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res 1118: 6-12, 2006.
165. Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N and Maruo T: Matrix metalloproteinase-1 and-9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 13: 523-529, 2006.
166. Kader AK, Shao L, Dinney CP, Schabath MB, WangY, Liu J, Gu J, Grossman HB and Wu X: Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66: 11644-11648, 2006.
167. Li Y, Jin X, Kang S, Wang Y, Du H, Zhang J, Guo W, Wang N and Fang S: Polymorphisms in the promoter regions of the matrix metalloproteinases-1,-3,-7, and-9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol 101: 92-96, 2006.
168. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E, Vylliotis A, Ragos V, Neukam FW and Patsouris E: Association of-1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res 27: 4095-4100, 2007.
169. Singh H, Jain M and Mittal B: MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol Oncol 110: 71-75, 2008.
170. Wu J, Zhang L, Luo H, Zhu Z, Zhang C and Hou Y: Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol 27: 553-557, 2008.
171. Alakus H, Afriani N, Warnecke-Eberz U, Bollschweiler E, Fetzner U, Drebber U, Metzger R, Hölscher AH and Mönig SP: Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. World J Surg 34: 2853-2859, 2010.
172. Chaudhary AK, Pandya S, Mehrotra R, Bharti AC, Jain S and Singh M: Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers 15: 684-692, 2010.
173. Altaş M, Bayrak OF, Ayan E, Bolukbasi F, Silav G, Coskun KK, Culha M, Sahin F, Sevli S and Elmaci I: The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochir (Wien) 152: 1611-1617, 2010.
174. Gil Ugarteburu R, Rivas del Fresno M, González Rodríguez I, González Arriaga P, López Cima F, Fernández Samoano A, Fernández García I, Benito García P, Muruamendiaraz Fernández V and Tardón A: Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch Esp Urol 63: 125-132, 2010.
175. Malik N, Kumar R, Prasad KN, Kawal P, Srivastava A and Mahapatra AK: Association of matrix metalloproteinase-1 gene polymorphism with glioblastoma multiforme in a northern Indian population. J Neurooncol 102: 347-352, 2011.
176. Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, Lin CW, Yang SF and Weng CJ: Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol 18: 2348-2356, 2011.
177. Lei Z, Liu R, Chen J, Zhou Q and Zhang H: [Meta Analysis of Association between Polymorphisms in Promoter Region of MMPs gene and Risk of Lung Cancer.]. Zhongguo Fei Ai Za Zhi 12: 381-386, 2009. (in Chinese).
178. Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP and Zhang C: Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 127: 813-818, 2011.
179. Zhang LY and Ren KW: Meta-analysis of MMP2-1306T allele as a protective factor in digestive cancer. Arch Med Res 42: 239-243, 2011.
180. Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, Zhang Z, Wang X and Yu L: Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis 25: 41-48, 2010.
181. Peng B, Cao L, Ma X, Wang W, Wang D andYu L: Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 25: 371-379, 2010.
182. Calingasan NY and Gibson GE: Dietary restriction attenuates the neuronal loss, induction of heme oxygenase-1 and blood-brain barrier breakdown induced by impaired oxidative metabolism. Brain Res 885: 62-69, 2000.
183. Beauchesne É, Desjardins P, Hazell AS and Butterworth RF: eNOS gene deletion restores blood-brain barrier integrity and attenuates neurodegeneration in the thiamine-deficient mouse brain. J Neurochem 111: 452-459, 2009.
184. KohdaY, Shirakawa H, Yamane K, Otsuka K, Kono T, Terasaki F and Tanaka T: Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 33: 459-472, 2008.
185. Tarallo S, Beltramo E, Berrone E, Dentelli P and Porta M: Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol 47: 105-111, 2010.
186. Gu B, Desjardins P and Butterworth RF: Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulvenerable brain regions of rats with experimental Wernicke's encepha-lopathy: effect of numesulide. Metab Brain Dis 23: 175-187, 2008.
187. Liu S, Stromberg A, Tai HH and Moscow JA: Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2: 477-487, 2004.
188. Tai HH, Tong M and Ding Y: 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat 83: 203-208, 2007.
189. Yaday UC, Subramanyam S and Ramana KV: Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 50: 2276-2282, 2009.
190. Yaday UC, Kalariya NM, Srivastava SK and Ramana KV: Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med 48: 1423-1434, 2010.
191. Shoeb M and Ramana KV: Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 52: 182-190, 2012.
192. Jabbour HN, Milne SA, Williams AR, Anderson RA and Boddy SC: Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 85: 1023-1031, 2001.
193. Kundu N, Yang Q, Dorsey R and Fulton AM: Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93: 681-686, 2001.
194. Gatalica Z, Lilleberg SL, Koul MS, Vanecek T, Hes O, Wang B and Michal M: COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors. Hum Pathol 39: 1495-1504, 2008.
195. Okawa T, Yoshinaga K, Uetake H, Sato T, Higuchi T, Nemoto T and Sugihara K: Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas. Dis Colon Rectum 47: 1915-1921, 2004.
196. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC and Sung JJ: Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 84: 335-339, 2001.
197. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP and Jabbour HN: Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86: 2243-2249, 2001.
198. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, Hylind LM, Offerhaus GJ, Giardiello FM and Goggins M: Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the-765G-> C COX-2 polymorphism. Clin Cancer Res 11: 4090-4096, 2005.
199. Markosyan N, Chen EP, Ndong VN, Yao Y, Sterner CJ, Chodosh LA, Lawson JA, Fitzgerald GA and Smyth EM: Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 32: 1441-1449, 2011.
200. Santander S, Cebrián C, Esquivias P, Conde B, Esteva F, Jiménez P, Ortego J, Lanas A and Piazuelo E: Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice. Int J Oncol 40: 527-534, 2012.
201. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001.
202. Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, Song YS, Kang D, Yoo KY, Kang SB and Lee HP: Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217: 11-16, 2005.
203. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, Deng J, Shen MC, Wang BS, Han TQ, Zhang BH, Cohen-Webb H, Yeager M, Welch R, Chanock S, Fraumeni JF Jr and Hsing AW: Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 27: 1251-1256, 2006.
204. Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, Kim CH, Kam S, Kang YM, Jung TH and Park JY: Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 6: 70, 2006.
205. Lira MG, Mazzola S, Tessari G, Malerba G, Ortombina M, Naldi L, Remuzzi G, Boschiero L, Forni A, Rugiu C, Piaserico S, Girolomoni G and Turco A: Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 157: 49-57, 2007.
206. Upadhyay R, Jain M, Kumar S, Ghoshal UC and Mittal B: Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res 663: 52-59, 2009.
207. Ben Nasr H, Chahed K, Bouaouina N and Chouchane L: PTGS2 (COX-2)-765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep 36: 193-200, 2009.
208. Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, Yu D, Li H, Zhao P and Lin D: Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 136: 1659-1668, 2009.
209. Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Palmieri RT, Cramer DW and Goodman MT: Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 21: 1731-1741, 2010.
210. Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM and Pharoah PD: Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 15: 2181-2191, 2009.
211. Li Y, He W, Liu T and Zhang Q: A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma. Mol Diagn Ther 14: 351-355, 2010.
212. Zheng J, Chen S, Jiang L,You Y, Wu D and ZhouY: Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol 87: 486-493, 2011.
213. Amirian ES, Ittmann MM and Scheurer ME: Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate 71: 1382-1389, 2011.
214. Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB and Manni JJ: COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 31: 938-943, 2009.
215. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA, Zhang J and Hebert JR: Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 24: 647-654, 2009.
216. Akkiz H, Bayram S, Bekar A, Akgöllü E and ÜlgerY: Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem 347: 201-208, 2011.
217. Dong J, Dai J, Zhang M, Hu Z and Shen H: Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 25: 1042-1050, 2010.
218. Zhu W, Wei BB, Shan X and Liu P:-765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37: 277-288, 2010.
219. Shrubsole MJ, Cai Q, Wen W, Milne G, Smalley WE, Chen Z, Ness RM and Zheng W: Urinary prostaglandin E2 Metabolite and Risk for Colorectal Adenoma. Cancer Prev Res (Phila) 5: 336-342, 2012.
220. 2) in Portal Blood in Patients with Pancreatic Tumor-A Single Institution Series. J Invest Surg 25: 8-13, 2012.
221. Rasmuson A, Kock A, Fuskevåg OM, Kruspig B, Simón- Santamaría J, Gogvadze V, Johnsen JI, Kogner P and Sveinbjörnsson B: Autocrine prostaglandin e(2) signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7: e29331, 2012.
222. Han S and Roman J: Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314: 1093-1099, 2004.
223. Gupta SC, Hevia D, Patchva S, Park B, Koh W and Aggarwal BB: Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy. Antioxid Redox Signal 16: 1295-1322, 2012.
224. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M and Sperlongano P: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 9: 171, 2011.
225. Zhang Q, Ma Y, Cheng YF, Li WJ, Zhang Z and Chen SY: Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer Lett 313: 201-210, 2011.
226. Wang HC and Choudhary S: Reactive oxygen species-mediated therapeutic control of bladder cancer. Nat Rev Urol 8: 608-616, 2011.
227. Rogalska A, Gajek A, Szwed M, Jóźwiak Z and Marczak A: The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol In Vitro 25: 1712-1720, 2011.
228. Gupta-Elera G, Garrett AR, Robison RA and O'Neill KL: The role of oxidative stress in prostate cancer. Eur J Cancer Prev 21: 155-162, 2012.
229. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ and Calle EE: Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 16: 1784-1794, 2007.
230. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J and Albanes D: Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14: 513-518, 2003.
231. Wang S, Wang F, Shi X, Dai J, PengY, Guo X, Wang X, Shen H and Hu Z: Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk-A meta-analysis. Eur J Cancer 45: 2874-2881, 2009.
232. Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, Li J and Chen Q: MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol 136: 975-979, 2010.
233. Ma X, Chen C, Xiong H, Fan J, Li Y, Lin H, Xu R, Huang G and Xu B: No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls. Breast Cancer Res Treat 122: 509-514, 2010.
234. Calingasan NY, Chun WJ, Park LC and Gibson GE: Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. J Neuropathol Exp Neurol 58: 946-958, 1999.
235. Lukienko PI, Mel'nichenko NG, Zverinskii IV and Zabrodskaya SV:Antioxidant properties of thiamine. Bull Exp Biol Med 130: 874-876, 2000.
236. De Souza Pinto R, Castilho G, Paim BA, Machado-Lima A, Inada NM, Nakandakare ER, Vercesi AE and Passarelli M: Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids 47: 443-450, 2012.
237. Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L and Gross ML, Adaikalakoteswari A, Thornalley PJ, Hammes HP, Nawroth PP, Zeier M, Schwenger V: Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 22: 914-926, 2011.
238. Mehta R, Dedina L and O'Brien PJ: Rescuing hepatocytes from iron-catalyzed oxidative stress using vitamins B1 and B6. Toxicol In Vitro 25: 1114-1122, 2011.
239. Le Pennec S, Mirebeau-Prunier D, Boutet-Bouzamondo N, Jacques C, Guillotin D, Lauret E, Houlgatte R, Malthièry Y and Savagner F: Nitric oxide and calcium participate in the fine regulation of mitochondrial biogenesis in follicular thyroid carcinoma cells 286: 18229-18239, 2011.
240. Bentz BG, Chandra R, Haines GK 3rd, Robinson AM, Shah P and Radosevich JA: Nitric oxide and apoptosis during human head and neck squamous cell carcinoma development. Am J Otolaryngol 23: 4-11, 2002.
241. Siripin D, Fucharoen S and Tanyong DI: Nitric oxide and caspase 3 mediated cytokine induced apoptosis in acute leukemia. Asian Pac J Allergy Immunol 29: 102-111, 2011.
242. Saleem W, Suzuki Y, Mobaraki A, Yoshida Y, Noda S, Saitoh JI and Nakano T: Reduction of nitric oxide level enhances the radiosensitivity of hypoxic non-small cell lung cancer. Cancer Sci 102: 2150-2156, 2011.
243. Guler E, Baspinar O, Cekmen M, Kilinc M and Balat A: Nitric oxide: a new biomarker of Doxorubicin toxicity in children? Pediatr Hematol Oncol 28: 395-402, 2011.
244. Chin MP and Deen WM: Prediction of nitric oxide concentrations in melanomas. Nitric Oxide 23: 319-326, 2010.
245. Ellie E, Loiseau H, Lafond F, Arsaut J and Demotes-Mainard J: Differential expression of inducible nitric oxide synthase mRNA in human brain tumours. Neuroreport 7: 294-296, 1995.
246. Zhang W, He XJ, MaYY, Wang HJ, Xia YJ, Zhao ZS,Ye ZY and Tao HQ: Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Hum Pathol 42: 1275-1282, 2011.
247. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, and Ambs S: Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120: 3843-3854, 2010.
248. Cardnell RJ and Mikkelsen RB: Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. Plos One 6: e20147, 2011.
249. Ryk C, Steineck G, Wiklund NP, Nyberg T and de Verdier PJ: The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis. J Urol 184: 2150-2157, 2010.
250. Shen CH, Wang YH, Wang WC, Jou YC, Hsu HS, Hsieh HY and Chiou HY: Inducible nitric oxide synthase promoter polymorphism, cigarette smoking, and urothelial carcinoma risk. Urology 69: 1001-1006, 2007.
251. Kaise M, Miwa J, Suzuki N, Mishiro S, Ohta Y, Yamasaki T and Tajiri H: Inducible nitric oxide synthase gene promoter polymorphism is associated with increased gastric mRNA expression of inducible nitric oxide synthase and increased risk of gastric carcinoma. Eur J Gastroenterol Hepatol 19: 139-145, 2007.
252. Arikan S, Cacina C, Guler E, Culcu S, Tuna G and Yaylim-Eraltan I: The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish population. Mol Biol Rep 39: 3245-3249, 2012.
253. Han X, Zheng T, Lan Q, ZhangY, Kilfoy BA, Qin Q, Rothman N, Zahm SH, Holford TR, Leaderer B and Zhang Y: Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 18: 1429-1438, 2009.
254. Hao Y, Montiel R and Huang Y: Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 124: 809-813, 2010.
255. Kruse M, Navarro D, Desjardins P and Butterworth RF: Increased brain endothelial nitric oxide synthase expression in thiamine deficiency: relationship to selective vulnerability. Neurochem Int 45: 49-56, 2004.
256. Luong K and Nguyen L: The impact of thiamine treatment on generalized anxiety disorder. Int J Clin Med 2: 439-443, 2011.